00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
22:14 , Feb 21, 2019 |  BC Extra  |  Company News

Management tracks: Mirati, Verastem, RedHill

Oncology company Mirati Therapeutics Inc. (NASDAQ:MRTX) named Faheem Hasnain as chairman. He succeeds Rodney Lappe, who is retiring but will remain a consulting adviser. Hasnain is executive chairman of Gossamer Bio Inc. (NASDAQ:GOSS), which raised...
21:36 , Jan 26, 2019 |  BioCentury  |  Product Development

Raising the BD bar

Innovator biotechs say that the business development bar has been raised for companies developing new modalities, with potential partners seeking proof of mechanism on top of proof of efficacy. A host of products based on...
01:19 , Oct 6, 2018 |  BioCentury  |  Finance

In sight of uncharted territory

Strong growth from small- and mid-caps coupled with a late run from large cap biotechs has pushed the sector within sight of its all-time high in 2015. Some buysiders now are seeing red flags of...
00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
19:25 , Oct 5, 2018 |  BC Week In Review  |  Company News

Deal adds HBV therapy to Janssen pipeline, validates Arrowhead platform

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) granted Janssen Pharmaceuticals Inc. rights to an HBV candidate for its curative combination toolbox. The deal, worth up to $3.7 billion, is Arrowhead's first billion dollar deal for a platform that...
11:31 , Oct 4, 2018 |  BC Extra  |  Company News

Deal satisfies Janssen HBV strategy, validates Arrowhead platform

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) granted Janssen Pharmaceuticals Inc. rights to an HBV candidate for its curative combination toolbox. The deal, worth up to $3.7 billion, is Arrowhead's first billion dollar deal for a platform that...
22:42 , Sep 21, 2018 |  BioCentury  |  Product Development

Arrowhead refills its quiver

Arrowhead Pharmaceuticals Inc.’s tox blowup in 2016 set back its clinical timelines, but it also prompted the company to bring a more versatile platform online faster than originally planned. Early data from replacement candidates suggest...
15:19 , Sep 14, 2018 |  BC Week In Review  |  Clinical News

Arrowhead's third-generation RNAi shows initial efficacy against HBV

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) reported initial data showing that monthly doses of its third-generation RNAi therapy ARO-HBV reduced circulating hepatitis B surface antigen (HBsAg) levels in a broad population of patients with chronic HBV infection....
20:42 , Sep 6, 2018 |  BC Extra  |  Clinical News

Arrowhead's third-generation RNAi shows initial efficacy against HBV

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) gained $5.29 (38%) to $19.39 Thursday after reporting initial data showing that monthly doses of its third-generation RNAi therapy ARO-HBV reduced circulating HBV surface antigen (HBsAg) in a broad population of...